Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/28—Insulins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/26—Glucagons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
  • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising at least one insulin and at least one GLP-1 receptor agonist, hereinafter referred to as GLP-1 agonist, wherein the medicament is formulated or / and formulated to contain the insulin and the GLP-1 agonist in each containing a predetermined dose and can be administered in each case adapted to the needs of a patient dose.
• the invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a first pharmaceutical composition and a second pharmaceutical composition and optionally at least one further pharmaceutical composition, each comprising at least one insulin and at least one GLP-1 agonist and the at least one insulin and / or the at least one GLP -1 agonists in different proportions by weight based on the total weight of the composition.
• the present invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a first pharmaceutical composition and a second pharmaceutical composition and optionally at least one further pharmaceutical composition, wherein the first pharmaceutical composition comprises at least one insulin, and wherein the second pharmaceutical composition comprises at least one insulin and at least one GLP 1 agonist, and wherein the at least one further pharmaceutical composition comprises at least one insulin and at least one further active ingredient.
• diabetes mellitus Around 250 million people worldwide suffer from diabetes mellitus. For the type 1 diabetics, substitution of missing endocrine insulin secretion is the only therapy currently possible. Those affected are lifelong, usually several times a day, rely on insulin injections. In contrast to type 1 diabetes, type 2 diabetes is not fundamentally deficient in insulin, however, treatment with insulin, optionally in combination with an oral antidiabetic, is considered to be the most favorable form of therapy in a large number of cases, especially at an advanced stage.
• the replacement of the body's insulin secretion by exogenous, usually subcutaneous administration of insulin generally does not approach the above-described quality of the physiological regulation of blood glucose. Often, derailments of blood glucose go up or down, which can be life threatening in their most severe forms. In addition, however, increased blood glucose levels without initial symptoms represent a considerable health risk over years.
• Diabetic late damage is microvascular and macrovascular damage, which may manifest as retinopathy, nephropathy, or neuropathy, leading to blindness, renal failure, and loss of extremities, in addition to an increased risk of cardiovascular disease. From this it can be deduced that an improved therapy of diabetes must first and foremost aim to keep the blood glucose as close as possible to the physiological range. According to the concept of intensified insulin therapy, this should be achieved by injections of fast-acting and slow-acting insulin preparations several times a day. Quick-acting formulations are given at mealtimes to offset the postprandial increase in blood glucose. Slow-acting basal insulins should ensure the basic supply of insulin, especially during the night, without leading to hypoglycemia to lead.
• Insulin is a 51 amino acid polypeptide distributed among 2 amino acid chains: the 21 amino acid A chain and the 30 amino acid B chain. The chains are linked by 2 disulfide bridges. Insulin preparations have been used for diabetes therapy for many years. Not only naturally occurring insulins are used, but more recently also insulin derivatives and analogues.
• Insulin analogs are analogues of naturally occurring insulins, viz
• Human insulin or animal insulins which differ in substitution of at least one naturally occurring amino acid residue with other amino acids and / or addition / removal of at least one amino acid residue from the corresponding otherwise identical naturally occurring insulin. These may also be amino acids that are not naturally occurring.
• Insulin derivatives are derivatives of naturally occurring insulin or an insulin analog, which are obtained by chemical modification.
• the chemical modification may e.g. in the addition of one or more particular chemical groups to one or more amino acids.
• insulin derivatives and insulin analogues have a slightly altered effect on human insulin.
• EP 0 214 826 Insulin analogs with accelerated onset of action are described in EP 0 214 826, EP 0 375 437 and EP 0 678 522.
• EP 0 214 826 relates inter alia. on
• EP 0 678 522 describes insulin analogues which have different amino acids in position B29, preferably proline, but not glutamic acid.
• EP 0 375 437 comprises insulin analogues with lysine or arginine in B28, which may optionally be additionally modified in B3 and / or A21.
• An accelerated effect is also exhibited by the insulin analogues described in EP-A-0 885 961.
• EP 0 419 504 discloses insulin analogs which are protected against chemical modifications by altering asparagine to B3 and at least one further amino acid in positions A5, A15, A18 or A21.
• insulin analogs are described in which at least one amino acid of positions B1 -B6 is replaced by lysine or arginine. Such insulins have a prolonged action according to WO 92/00321.
• the insulin analogues described in EP-A 0 368 187 and in German Patent Applications Nos. 10 2008 003 568.8 and 10 2008 003 566.1 also have a delayed action.
• the insulin preparations on the market of naturally occurring insulin for insulin substitution differ in the source of insulin (e.g., beef, pork, human insulin) and the composition with which the profile of action (onset and duration of action) can be affected.
• the profile of action onset and duration of action
• Recombinant DNA technology nowadays enables the production of such modified insulins.
• These include insulin glargine (Gly (A21) Arg (B31) Arg (B32) human insulin) with a prolonged duration of action.
• Insulin glargine is injected as an acidic, clear solution and precipitates as a stable hexamer associate due to its solubility in the physiological pH range of the subcutaneous tissue.
• Insulin glargine is injected once daily and is distinguished from other long-acting insulins by its low serum profile and the associated reduction in the risk of nocturnal hypoglycemia (Schubert-Zsilavecz et al., 2: 125-130 (2001)).
• the specific preparation of insulin glargine which leads to the extended duration of action, is characterized by a clear solution with acidic pH.
• Glucagon-like peptide 1 (GLP-1) is an endocrine hormone that causes the
• GLP-1 Insulin response after oral intake of glucose or fat increased. GLP-1 generally regulates glucagon levels, slows gastric emptying, stimulates (in) insulin biosynthesis, increases sensitivity to insulin and stimulates insulin-independent glycogen biosynthesis (Holst (1999), Curr. Med. Chem. 6: 1005, Nauck et al. (1997) Exp Clin Endocrinol Diabetes 105: 187 , Lopez-Delgado et al. (1998) Endocrinology 139: 281 1).
• GLP-1 has 37 amino acid residues (Heinrich et al., Endocrinol. 1 15: 2176 (1984), Uttenthal et al., J Clin Endocrinol Metabol (1985) 61: 472). Active fragments of GLP-1 include GLP-1 (7-36) amide and GLP-1 (7-37).
• Exendins are another group of peptides that use the
• Exendins have some similarity in sequence to GLP-1 (7-36) (53%, Goke et al., J. Biol Chem 268, 19650-55).
• Exendin-3 and exendin-4 stimulate an increase in cellular cAMP production in guinea pig pancreas acinar cells by interaction with exendin receptors (Raufman, 1996, Reg. Peptides 61: 1-18).
• Exendin-3 unlike exendin-4, causes an increase in amylase release in pancreatic acinar cells.
• Exendin-3, exendin-4 and exendin agonists have been proposed for the treatment of diabetes mellitus and the prevention of hyperglycemia, reducing gastric motility and depletion (US 5,424,286 and WO98 / 05351).
• Exendin analogs may be characterized by amino acid substitutions and / or C-terminal truncation of the native exendin-4 sequence. Such exendin analogs are described in WO 99/07404, WO 99/25727, WO 99/25728.
• Combinations of insulin and GLP-1 are known from WO 2004/005342 for the treatment of diabetes.
• the amount of insulin to be administered is adjusted to the individual needs of individual diabetic patients. Individual patients usually require different amounts of insulin or / and GLP-1 agonist.
• the predetermined dose is administered by administering a predetermined amount of a composition of defined concentration.
• a composition containing insulin and GLP-1 simultaneously allows the administration of only a specific ratio of insulin and GLP-1. This means that only one of the two amounts of insulin and GLP-1 can be optimally adapted to the needs of the patient. Since in practice the correct adjustment of the administered amount of insulin is essential, it can be assumed that the administration of a certain ratio of insulin to GLP-1 of the GLP-1 agonist is either under- or over-dosed and possibly coincidentally correct.
• the active ingredients may be formulated in a composition and used in a device, e.g. in a pre-filled syringe.
• a device e.g. in a pre-filled syringe.
• Such a system allows the dosage of the combination, but only in a fixed ratio of the active ingredients, as contained in the composition.
• this is disadvantageous for the combination of an insulin with a GLP-1 agonist because different amounts of the insulin and the GLP-1 agonist must be administered depending on the therapeutic need.
• two active agents can be administered in two separate formulations, each containing one of the two active ingredients and injected independently with one device (e.g., pre-filled syringes).
• an injection therapy such as Injection of insulin is the patient's compliance essential to the success of the therapy.
• the pain, a needle phobia the ability to take the injection device with it a problem, which can lead to a reduced compliance. If the patient uses two separate devices for injection, these problems increase.
• a single device for administering insulin and a GLP-1 agonist is against the use of two separate devices for administering Insulin and a GLP-1 agonist beneficial to the patient / user.
• using only one device instead of two devices can reduce the number of steps that the patient / user must perform, which reduces the frequency of application errors. This reduces the risk of unwanted side effects.
• US 4,689,042, US 5,478,323, US 5,253,785 and WO 01/02039 describe devices for the simultaneous administration of two injectable products to a patient. These devices contain two containers, each containing a composition. In these devices, the injection of both compositions is via a needle. Thus, while the disadvantages can be overcome, which arise with the use of two separate devices. The mixture dilutes the concentrations of the two active ingredients. This can be detrimental to the pharmacokinetics.
• the pharmacokinetics of insulin is affected by the dilution of insulin in the administered composition.
• the concentration of insulin should be kept as constant as possible.
• the dosage should be essentially via the volume of insulin composition administered. This also applies to the administration of a combination of insulin and a GLP-1 agonist. When administering a combination of insulin and a GLP-1 agonist, this requirement can only be met if both substances in a composition are dosed in a fixed ratio.
• both substances are provided in separate compositions and mixed in a suitable device (eg from WO 01/02039) for injection, a constant insulin concentration can only be achieved if the insulin composition is not substantially diluted by the composition of the GLP-1 agonist.
• a suitable device eg from WO 01/02039
• a constant insulin concentration can only be achieved if the insulin composition is not substantially diluted by the composition of the GLP-1 agonist.
• an independent dosage of insulin and the GLP-1 agonist is limited.
• a conceivable solution would be to provide the GLP-1 agonist in such a high concentration that the addition of the GLP-1 agonist causes no significant dilution of the insulin composition (eg not more than 10%).
• Polypeptides such as insulins (eg insulin glagin, Lantus ® ) or GLP-1 agonists can not be concentrated at will.
• Agonists is not or not significantly affected by the concentration / dilution.
• An article of the invention is a pharmaceutical composition comprising at least one insulin and at least one GLP-1 agonist, the drug being so formulated or / and is formulated to contain the insulin and the GLP-1 agonist in a predetermined amount, respectively, and to be administered in a dose each adapted to the needs of a patient.
• the medicament according to the invention is used in particular for the treatment of patients with diabetes mellitus, in particular of patients with diabetes type 1 or type 2.
• the blood glucose concentration in patients with diabetes in particular diabetes type 1 or type 2
• the pharmaceutical composition of the invention is for adjusting the postprandial and / or postabsorptive blood glucose concentration of Patients with diabetes used, especially of patients with type 1 or type 2 diabetes. Adjustment in this context means that normoglycemic blood glucose concentrations are substantially achieved or at least approximated. Under normoglycemic values, blood glucose concentrations in the standard range (fluctuation range 60-140 mg / dl corresponding to 3.3 to 7.8 mmol / l) are understood in particular. This range includes blood glucose levels in fasting conditions, postprandial and postabsorptive conditions.
• Postprandial and postabsorptive are terms familiar to the skilled person in the field of diabetology.
• postprandial it is meant in particular the phase after a meal or / and after a glucose load in the experiment. This phase is characterized in particular in the healthy by an increase and decrease in the blood glucose concentration.
• a postabsorptive or postabsorptive phase this refers in particular to the phase following the postprandial phase.
• the postprandial phase typically ends up at 4 h after the meal and / or glucose load.
• the postabsorptive phase typically lasts up to 8 to 16 h.
• the medicament of the invention is preferably used to improve glucose tolerance in the treatment of a patient with diabetes, in particular with Type 1 or Type 2 diabetes.
• improving the glucose tolerance it is understood that the postprandial blood glucose concentration is lowered by the medicament according to the invention.
• improving the glucose tolerance means that the postabsorptive blood glucose concentration is lowered by the medicament according to the invention.
• Reduction means, in particular, that the blood glucose concentration substantially reaches or at least approaches normoglycemic values.
• the medicament of the invention can reduce the risk of hypoglycemia, which z. B. may occur in the postabsorptive phase.
• the medicament according to the invention is preferably used for the prevention of hypoglycemia in the treatment of a patient with diabetes, in particular with type 1 or type 2 diabetes, the hypoglycemia occurring in particular in the postabsorptive phase.
• the medicament according to the invention can obtain the function of the ß-cells of the pancreas.
• the medicament according to the invention is preferably used for the prevention of a loss of function of the ß-cells of the pancreas in a patient with diabetes, in particular with a diabetes type 1 or type 2.
• the loss of function of the ⁇ -cells may be caused in particular by apoptosis.
• the medicament according to the invention can cause a weight loss or / and be used to prevent weight gain in patients with diabetes, in particular type I or II. In diabetes patients, especially type 2, weight gain and obesity are common problems.
• the administration of the medicament of the invention can support a therapy for the treatment of obesity.
• the drug of the present invention can be used to treat more than one of the preferred indications described herein in a patient with diabetes, particularly a Type 1 or 2 diabetes. Therefore, not only the individual preferred indications are encompassed by the present invention, but also any combination of the indications.
• the pharmaceutical composition according to the invention can therefore be used for the treatment of one or more of the indications described herein in patients with diabetes, in particular patients with diabetes type 1 or type 2, e.g.
• the postprandial and / or the postabsorptive blood glucose concentration for the improvement of glucose tolerance, for the prevention of hypoglycemia, for the prevention of a functional loss of the ß-cells of the pancreas, for weight loss and / or for the prevention of weight gain.
• Preference is given to discontinuing fasting, postprandial and / or postabsorptive blood glucose concentrations, improving glucose tolerance or / and preventing hypoglycaemia.
• the pharmaceutical composition of the invention may also be used for the manufacture of a medicament for the treatment of one or more of the indications described herein, e.g. To halt fasting, postprandial and / or postabsorptive blood glucose levels, to improve glucose tolerance, to prevent hypoglycemia, to prevent pancreatic beta cell function loss, to lose weight and / or to prevent weight gain.
• the at least one insulin and the at least one GLP-1 agonist may also be used to prepare a medicament for the treatment of one or more of the indications described herein, e.g. For the adjustment of the fasting, the postprandial and / or the postabsorptive blood glucose concentration, for the improvement of the glucose tolerance, for the prevention of a hypoglycemia, for the prevention of a functional loss of the ß-cells of the
• an article of the invention is a pharmaceutical composition comprising a first pharmaceutical composition and a second pharmaceutical composition and optionally at least one further pharmaceutical composition each comprising at least one insulin and at least one GLP-1 agonist and containing at least one insulin and / or the at least one Containing GLP-1 agonists in different proportions by weight based on the total weight of the composition.
• “optionally at least one further pharmaceutical composition” means that the medicaments according to the invention may comprise, in addition to the first and the second pharmaceutical composition, at least one further pharmaceutical composition.
• the medicament of the invention can thus z. 3, 4, 5, 6, 7, 8, 9, 10 or more pharmaceutical compositions of the invention.
• medicaments which contain a first and a second pharmaceutical composition according to the invention.
• compositions containing a first, a second and a third pharmaceutical composition according to the invention.
• compositions containing a first, a second, a third and a fourth pharmaceutical composition according to the invention.
• compositions containing a first, a second, a third, a fourth and a fifth pharmaceutical composition.
• the proportions by weight of the at least one insulin and the at least one GLP-1 agonist may be selected in the first pharmaceutical composition, the second pharmaceutical composition and optionally at least one further pharmaceutical composition such that the pharmaceutical compositions have different ratios of insulin to GLP-1 Agonists based on the weight fraction.
• the first composition may contain the smallest ratio and the second composition the next larger ratio. If at least one further composition is present, this may contain the next larger ratio. If another composition is present, this in turn may contain the next larger ratio.
• the compositions may contain increasing ratios of insulin to GLP-1 agonist based on weight fraction from the first to the second and optionally further compositions.
• the proportion by weight of one of the two active substances, ie the at least one insulin or the at least one GLP-1 agonist, in the first pharmaceutical composition, the second pharmaceutical composition and optionally at least one further pharmaceutical composition is preferably in each case selected such that by administration a predetermined volume of the first, second or / and at least one further composition, the predetermined dose of this active ingredient can be administered.
• This active substance is particularly preferably the at least one insulin.
• the proportion by weight of the other of the two active substances, ie the at least one insulin or the at least one GLP-1 agonist, in the first pharmaceutical composition, the second pharmaceutical composition and optionally at least one further pharmaceutical composition is preferably selected such that the ratios of Insulin to GLP-1 agonists based on the proportion by weight of the first to the second and optionally further compositions increase.
• this active ingredient the at least one GLP-1 agonist.
• the weight fraction of the other of the two active ingredients in the pharmaceutical compositions is determined so that one of the pharmaceutical compositions can be selected such that the dose of the first of the two active ingredients to be administered and the dose of the second active ingredient to be administered are given in a particular volume are.
• a pharmaceutical composition containing the desired ratio is selected.
• a pharmaceutical composition could be provided to achieve optimal on-demand dosage for both agents for each patient.
• a certain number of pharmaceutical compositions are sufficient to cover the dosages required in practice for both drugs.
• a particular dosage range is determined within a therapeutically reasonable interval for each of the two drugs.
• the dose to be administered is intended to vary substantially within this dosage range for a particular patient, without overdosing or underdosing.
• the synergistic concentration range of the GLP-1 agonist makes it possible for a pharmaceutical composition according to the invention which has a specific ratio of at least one insulin comprising at least one GLP-1 agonist, covering a therapeutic range of insulin doses contemporaneously with the associated synergistic amount of GLP-1 agonist.
• the ratio may be selected such that for any desired insulin dosage, a dosage of the at least one GLP-1 agonist corresponding to within the desired range, eg, the synergistic range, will be present.
• the ratios of the first, second and optionally at least one further composition of the medicament can furthermore be selected so that the ratios increase from the first to the second and optionally at least one further composition. If the dosage of the GLP-1 agonist at the desired insulin dosage of one composition (eg, the first composition) is outside (usually above) the desired dosage range of the GLP-1 agonist, the next composition (eg, the second Composition) or another composition having a greater ratio of the at least one insulin to the at least one GLP-1 agonist for use in which the amount of GLP-1 agonist is in the desired range at the desired insulin dose.
• the ratios of the first, second and optionally at least one further composition of the medicament can furthermore be selected such that the regions of the insulin dosages which correspond to the desired dosages of the at least one GLP-1 agonist adjoin one another and / or overlap one another. Preferably, the areas overlap.
• overlapping means that at least two compositions can be selected which at the desired dosage of the at least one insulin each contain an amount of the at least one GLP-1 agonist which is within the desired dosage range.
• compositions are sufficient to adjust the dose of the at least one insulin for an individual patient to a value selected from the range of 15 to 80 units of insulin and at the same time to the GLP-1 agonist at a level within the range of 10 to 20 ⁇ g dose (see Example 1 1).
• a pharmaceutical composition according to the invention can be provided in which the ratio is selected such that for each desired dosage of the GLP-1 agonist a dosage of the at least one insulin corresponding to the desired range, eg the synergistic range, is present.
• the ratios of the first, second and optionally at least one further composition of the medicament can furthermore be selected such that the ranges of the dosages of the GLP-1 agonist which correspond to the desired dosages of the at least one insulin join or overlap one another , Preferably, the areas overlap.
• Overlapping in this context means, in particular, that at least two compositions can be selected which at the desired dosage of the at least one GLP-1 agonist each contain an amount of the at least one insulin which is within the desired dosage range.
• the pharmaceutical composition of the invention contains at most 10 pharmaceutical compositions as defined above, more preferably at most 5, at most 4, at most 3 or 2 pharmaceutical compositions.
• the compositions according to the invention may contain the at least one insulin in respectively identical or different proportions by weight.
• at least two of the compositions of the invention may contain the at least one insulin in a substantially identical proportion by weight.
• Composition containing at least one insulin in a substantially identical proportion by weight and containing the at least one GLP-1 agonist in different proportions by weight.
• compositions according to the invention may contain the at least one GLP-1 agonist in respectively identical or different proportions by weight.
• at least two of the invention Compositions containing at least one GLP-1 agonist in a substantially identical proportion by weight.
• first, second and optionally further compositions contain the at least one GLP-1 agonist in a substantially identical weight fraction and contain at least one insulin in different proportions by weight.
• the medicament according to the invention may contain at least one further pharmaceutical composition which contains either at least one insulin or at least one GLP-1 agonist.
• the pharmaceutical composition according to the invention may contain at least one further pharmaceutical composition which contains at least one insulin and at least one GLP-1 agonist in a ratio of the weight proportions to the first, second or optionally further pharmaceutical composition described herein.
• a further subject of the invention is a pharmaceutical composition
• a pharmaceutical composition comprising a first pharmaceutical composition and a second pharmaceutical composition, wherein the first pharmaceutical composition comprises at least one insulin and the second pharmaceutical composition comprises at least one GLP-1 agonist and wherein the medicament is for independently administering the first and second pharmaceutical composition is formulated and / or formulated.
• Example 12 demonstrates how a combination of two or more active agents can be formulated so that when two or more compositions are combined, both active ingredients in any amount and in any desired amount
• Ratios can be administered to each other. This takes into account that at least one of the active ingredients by the combination (eg by mixing immediately before administration) should not be diluted.
• the present invention provides a pharmaceutical composition which comprises a first active ingredient and a second active ingredient and optionally at least one further active ingredient, wherein these active ingredients are provided in a first, a second and optionally at least one further composition.
• the first active ingredient is included in all compositions.
• the second active ingredient is included in the second formulation, and optionally at least one further active ingredient is included in the optional at least one other composition.
• the second and any further compositions contain the first active ingredient combined with another active ingredient.
• another object of the present invention is a pharmaceutical composition
• a pharmaceutical composition comprising a first pharmaceutical composition and a second pharmaceutical composition and optionally at least one further pharmaceutical composition, wherein the first pharmaceutical composition comprises at least a first active ingredient, and wherein the second pharmaceutical composition at least a first Active ingredient and at least one second active ingredient, and wherein the at least one further pharmaceutical composition comprises at least one first and at least one further active ingredient.
• the active ingredients may be any active ingredients.
• the first composition contains as active ingredient only the at least one first active ingredient.
• the first, second and optionally at least one further composition may contain the first active ingredient in a substantially equal weight fraction or in different proportions by weight based on the total weight of the composition.
• the first pharmaceutical composition, the second pharmaceutical composition and optionally at least one further pharmaceutical composition containing the first active ingredient in substantially equal proportions by weight based on the total weight of the composition.
• any ratio of the first and the second and optionally any ratio of the first and the at least one further composition can be used, wherein the dosage of the first active ingredient takes place over the total amount of the administered compositions.
• the amount of the active ingredient, which is contained only in the second and optionally the at least one further composition can be added continuously.
• any desired amount and any desired ratio of the first to the second active ingredient and optionally of the first active ingredient can be readily dosed to a further active ingredient without changing the concentration of the first active ingredient.
• the first active ingredient may be at least one insulin.
• the second active ingredient may be at least one GLP-1 agonist.
• Preferred is a pharmaceutical composition comprising a first pharmaceutical composition and a second pharmaceutical composition and optionally at least one further pharmaceutical composition, wherein the first pharmaceutical composition comprises at least one insulin, and wherein the second pharmaceutical
• Composition comprises at least one insulin and at least one GLP-1 agonist, and wherein the at least one further pharmaceutical composition comprises at least one insulin and at least one further active ingredient.
• the first composition contains as active ingredient only the at least one insulin.
• the other active ingredient may be any active ingredient.
• the other active ingredient is an active ingredient which is used for the treatment of patients with diabetes mellitus (type 1 or / and type 2), including active ingredients for the treatment of comorbidities of diabetes are included.
• the first, second and optionally at least one further composition may contain the insulin in a substantially equal weight fraction or in different proportions by weight based on the total weight of the composition.
• the first pharmaceutical composition, the second pharmaceutical composition and optionally at least one further pharmaceutical composition contain the insulin in substantially equal proportions by weight based on the total weight of the composition.
• any desired ratio of the first and the second and optionally any ratio of the first and the at least one further composition can be used, wherein the dosage of the insulin takes place over the total amount of the administered compositions.
• the amount of the active ingredient, which is contained only in the second and optionally the at least one further composition can be added continuously.
• any desired amount and any desired ratio of insulin to GLP-1 agonist and optionally of insulin to another active ingredient can readily be dosed without the concentration of the at least one insulin changing.
• substantially equal proportions by weight of an active ingredient in two compositions means that one of the two compositions contains the active ingredient in a proportion by weight which is e.g. not more than 10%, not more than 5%, not more than 1% or not more than 0.1% higher than its weight in the other composition.
• the first active ingredient may be at least one GLP-1 agonist.
• the second active ingredient may be at least one insulin.
• a pharmaceutical composition comprising a first pharmaceutical composition and a second pharmaceutical composition and optionally at least one further pharmaceutical composition, wherein the first pharmaceutical composition comprises at least one GLP-1 agonist, and wherein the second pharmaceutical Composition comprises at least one GLP-1 agonist and at least one insulin, and wherein the at least one further pharmaceutical composition comprises at least one GLP-1 agonist and at least one further active ingredient.
• the first composition contains as active ingredient only the at least one GLP-1 agonist.
• the first, second, and optionally at least one other composition may contain the GLP-1 agonist in a substantially equal weight fraction or in different proportions by weight based on the total weight of the
• composition included. It is preferred that the first pharmaceutical composition, the second pharmaceutical composition and optionally at least one further pharmaceutical composition comprise the at least one GLP-1 agonist in substantially equal proportions by weight based on the total weight of the composition.
• the present invention provides a pharmaceutical composition which has several advantages over prior art compositions comprising separate compositions each comprising an active ingredient, in particular an insulin or a GLP-1 agonist:
• the ratio of the first active ingredient to the second active ingredient and optionally of the first active ingredient to the at least one further active ingredient can be freely selected by the user. Since the first active ingredient is present in all compositions, in particular in equal parts by weight, this active ingredient is not diluted when the first composition is mixed with the second and optionally further compositions. This is important for drugs such as insulin, where the pharmacokinetics is influenced by the concentration / dilution. • The injection volume is reduced (see example 12). This reduces the dilution of the second active ingredient (eg of a GLP-1 agonist) and optionally of another active ingredient.
• the second active ingredient eg of a GLP-1 agonist
• kits comprising a pharmaceutical composition according to the invention.
• the kit according to the invention may be intended for use by medical personnel or by medical laypersons, in particular the patient himself or assistants such as relatives.
• the individual pharmaceutical compositions which comprise the medicament according to the invention are combined in separate packages, so that the patient can select the composition adapted to the current requirement and administer an appropriate amount.
• the kit according to the invention comprises, for example, the medicament according to the invention in the form of a set of syringes, glass ampoules and / or pins which contain a composition according to the invention.
• the medicament according to the invention can be administered in various ways.
• the drug can be administered parenterally.
• the drug can be injected using injection systems with or without a hypodermic needle.
• the drug can be administered by inhalation.
• liquid compositions can be inhaled, above the compositions can be inhaled in the form of powder.
• the medicament according to the invention can be administered by spray, in particular nasal spray.
• the drug of the invention can be administered by a transdermal system. The expert knows this
• compositions of the medicament of the invention are liquid.
• medicament according to the invention is administered parenterally, in particular injected.
• Another object of the present invention is a device for Administration of the medicament according to the invention.
• This device comprises the pharmaceutical compositions comprised by the pharmaceutical composition of the invention in separate containers and allows the dosage of the pharmaceutical compositions independently.
• the device according to the invention may be a device for parenteral administration.
• the device according to the invention may include a device for injection with or without an injection needle.
• the device may be an inhalation device wherein liquid compositions are inhaled, above which the compositions may be inhaled in the form of powder.
• the device may be a device for administering a spray, in particular a nasal spray.
• the device may be a transdermal delivery system. It is preferred that the device according to the invention is a device for parenteral administration, in particular an injection device.
• Packaging is a term which is known to the person skilled in the art and describes in pharmacology the final treatment, for example portioning and packaging, of medicaments for use by the end user
• "made-up” or “packaging” means, in particular, in that the pharmaceutical compositions according to the invention are suitably packaged in a therapeutically effective amount in order to enable the selection of at least one of the compositions of the medicament according to the invention for the desired dosage of the at least one insulin and the at least one GLP-1 agonist parenteral administration, preferably an injection, more preferably for subcutaneous injection
• a suitable package is, for example, a syringe or a glass jar with a suitable closure from which individual therapeutically effective doses may be withdrawn if desired
• injection pens for administration of insulin containing a container (e.g.
• a cartridge comprising a pharmaceutical composition of the invention.
• "Formulation” or “formulation” is a term known to those of skill in the art and refers to the production of drugs and drug compositions and the preparation of excipients in the field of pharmacology.
• “formulating” or “formulation” means, in particular, that the composition of the invention is provided in a suitable form which enables administration of a therapeutically effective amount of the active ingredients.
• a formulation for parenteral administration preferably for injection, more preferably for subcutaneous injection, is provided.
• GLP-1 agonist includes GLP-1, analogs and derivatives thereof, exendin-3 and analogs and derivatives thereof, exendin-4 and analogs and derivatives thereof.
• the compositions of the invention comprise one or more independently selected from the group consisting of glucagon-like peptide-1 (GLP-1), analogs and derivatives of GLP-1, exendin-3, analogs and derivatives of exendin-3, exendin-4 , Analogs and derivatives of exendin-4 and pharmacologically tolerable salts thereof. Also included are substances having the biological activity of GLP-1.
• GLP-1 analogs and derivatives are described, for example, in WO 98/08871, exendin-3, analogs and derivatives of exendin-3, exendin-4 and analogs and derivatives of exendin-4 can be found in WO 01/04156, WO 98/30231 , US 5,424,286, in the EP application 99 610043.4, in WO 2004/005342 and WO 04/035623 are found. These documents are incorporated herein by reference.
• the exendin-3, exendin-4 and analogs and derivatives thereof described therein can be used in the compositions of the present invention as GLP-1 agonists.
• any combination of the exendin-3, exendin-4 and the analogues and derivatives described therein in these documents can be used as GLP-1 agonists.
• the at least one GLP-1 agonist is preferably independently selected from the group consisting of exendin-4, analogs and derivatives of exendin-4 and pharmacologically tolerable salts thereof.
• Another preferred GLP-1 agonist is an analog of exendin-4 selected from a group consisting of: H-desPro 36 -exendin-4-Lys 6 -NH 2 , H-des (Pro 36 37 ) -exendin-4 Lys 4 -NH 2 ,
• Another preferred GLP-1 agonist is an analogue of exendin-4 selected from a group consisting of: the pro 36 [Asp 28 ] exendin-4 (1-39), the pro 36 [I soAsp 28 ] exendin-4 (1- 39), Pro 36 [Met (O) 14 , Asp 28 ] Exendin-4 (1-39), Pro 36 [Met (O) 14 , I soAsp 28 ] Exendin-4 (1-39), Pro 36 [Trp (O 2 ) 25 , Asp 28 ] Exend in-2 (1 -39), the Pro 36 [Trp (O 2 ) 25 , IsoPs 28 ] Exendin-2 (1 -39), the Pro 36 [Met (O) 14 Trp (O 2 ) 25 , Asp 28 ] exendin-4 (1-39), the Pro 36 [Met (O) 14 Trp (O 2 ) 25 , I soAsp 28 ] Exendin-4 (1-39) and pharmacologically tolerable salts thereof ,
• Another preferred GLP-1 agonist is an analog of exendin-4 selected from a group as described in the previous paragraph, in which the C-termini of the analogs of exendin-4 is added with the peptide -LyS 6 -NH 2 .
• Another preferred GLP-1 agonist is an analog of exendin-4 selected from a group consisting of:
• GLP-1 agonist is selected from a group consisting of Arg 34 , Lys 26 (N ⁇ ( ⁇ -glutamyl (N ⁇ -hexadecanoyl)), GLP-1 (7-37) [liraglutide] and a pharmacologically tolerable Salt of it.
• Another preferred GLP-1 agonist is AVE0010.
• AVE0010 assigns the sequence:
• At least one GLP-1 agonist includes combinations of the GLP-1 agonists described herein used in the compositions of the invention, e.g., any combination of two or more GLP-1 agonists selected from those herein described GLP-1 agonists.
• the at least one GLP-1 agonist is also preferably independently selected from exendin-4, Pro 36 exendin-4 (1-39) -Lys 6 -NH 2 and Arg 34 , l_ys 26 (N ⁇ ( ⁇ -glutamyl (N ⁇ - hexadecanoyl))) GLP-1 (7-37) [liraglutide] and pharmacologically tolerable salts thereof.
• compositions according to the invention contain the GLP-1 agonist in an amount of 10 ⁇ g / ml to 20 mg / ml, preferably 25 ⁇ g / ml to 15 mg / ml.
• the acidic to neutral dissolved GLP-1 agonists is preferably 20 ug / ml to 300 ug / ml and for the neutral to basic preferably 500 ug / ml to 10 mg / ml.
• exendin-4 analogues preferably 20 ⁇ g / ml to 150 ⁇ g / ml.
• insulin includes not only unmodified insulins but also insulin analogs, insulin derivatives, and insulin metabolites.
• the compositions of the invention comprise one or more independently selected from the group consisting of insulins (e.g., unmodified insulins), insulin analogs, insulin derivatives and insulin metabolites, and any combinations thereof.
• the at least one insulin may be independently selected from the group consisting of bovine insulins, analogs, derivatives and metabolites thereof, porcine insulins, analogs, derivatives and metabolites thereof and human insulins, analogs, derivatives and metabolites thereof.
• the at least one insulin is independently selected from human insulins, analogs, derivatives and metabolites thereof.
• an insulin according to the invention can be produced independently from unmodified insulins in particular from bovine insulins, porcine insulins and human insulins.
• the at least one insulin may be independently selected from the group consisting of bovine insulins, porcine insulins and human insulins. More preferably, the at least one insulin is independently selected from human insulins.
• An insulin according to the invention may be selected from unmodified insulins, in particular from bovine insulins, porcine insulins and human insulins.
• Insulin derivatives according to the invention are derivatives of a naturally occurring insulin or / and an insulin analog, which are obtained by chemical modification.
• the chemical modification may e.g. in the addition of one or more particular chemical groups to one or more amino acids.
• Insulin analogs which are described in EP 0 214 826, EP 0 375 437, EP 0 678 522, EP 0 885 961, EP 0 419 504, WO 92/00321, German Patent Applications No. 10 2008 003 568.8 and No. 10 2008 003 566.1 and EP-A 0 368 187 may be part of the compositions according to the invention.
• the documents are described in EP 0 214 826, EP 0 375 437, EP 0 678 522, EP 0 885 961, EP 0 419 504, WO 92/00321, German Patent Applications No. 10 2008 003 568.8 and No. 10 2008 003 566.1 and EP-A 0 368 187 may be part of the compositions according to the invention.
• the documents which are described in EP 0 214 826, EP 0 375 437, EP 0 678 522, EP 0 885 961, EP 0 419 504, WO 92/00
• EP 0 214 826, EP 0 375 437, EP 0 678 522, EP 0 419 504, WO 92/00321 and EP-A 0 368 187 are incorporated herein by reference.
• a preferred insulin analog of the invention may be selected from the group consisting of Gly (A21) -Arg (B31) -Arg (B32) human insulin (insulin glargine, Lantus); Arg (A0) -His (A8) -Glu (A15) -Asp (A18) -Gly (A21) -Arg (B31) -Arg (B32) - human insulin amide, Lys (B3) -Glu (B29) human insulin; Lys B28 Pro B29 human insulin (insulin lyspro), B28 asp human insulin (insulin aspart), human insulin in which proline in position B28 has been substituted by Asp, Lys, Leu, VaI or Ala and where in position B29 Lys may be substituted by Pro can; AlaB26 human insulin; Des (B28-B30) - human insulin; Des (B27) -human insulin or B29Lys ( ⁇ -tetradecanoyl), of (B30) - Human insulin (
• a preferred insulin derivative according to the invention can be selected from the group consisting of B29-N-myristoyl des (B30) human insulin, B29-N-palmitoyl des (B30) human insulin, B29-N-myristoyl human insulin, B29-N-palmitoyl human insulin, B28-N-myristoyl Lys B28 Pro B29 human insulin, B28-N-palmitoyl-Lys B28 Pro B29 human insulin, B30-N-myristoyl-Thr B29 Lys B30 human insulin, B30-N-palmitoyl-Thr B29 Lys B30 human insulin, B29-N - (N-palmitoyl-Y-glutamyl) -des (B30) human insulin, B29-N- (N-lithocholyl-Y-glutamyl) -des (B30) human insulin, B29-N- ( ⁇ -carboxyheptadecanoyl) -des (B30 ) Human insulin and B
• a more preferred insulin derivative of the invention is selected from the group consisting of Gly (A21) -Arg (B31) -Arg (B32) human insulin, Lys B28 Pro B29 human insulin (insulin Lyspro), B28 Asp human insulin (insulin aspart), B29Lys ( ⁇ - tetradecanoyl), B30 human insulin (insulin detemir).
• At least one insulin includes combinations of the insulins described herein, analogs, derivatives and metabolites thereof used in the compositions of the invention, for example, any combinations of two or more selected from the insulins described herein, analogs, derivatives and metabolites.
• compositions of the invention contain 60-6000 nmol / ml, preferably 240-3000 nmol / ml of an insulin as defined herein.
• a concentration of 240-3000 nmol / ml corresponds, depending on the insulin used, to a concentration of 1, 4-35 mg / ml or 40-500 units / ml.
• the compositions are in the range of 20 ⁇ g / ml GLP-1 agonist and 100 U / ml insulin to 300 ⁇ g / ml GLP-1 agonist and 500 U / ml insulin.
• concentration ranges are preferred: 25 ⁇ g / ml and 100 U / ml, 33 ⁇ g / ml and 100 U / ml, 40 ⁇ g / ml and 100 U / ml, 66 ⁇ g / ml and 100 U / ml and 75 ⁇ g / ml and 100 U / ml.
• the desired dosage range of the insulin is in particular a dosage with a synergistic effect.
• the values are 5 to 100 U, preferably 15 to 80 U.
• the values for the dosage range are 5 ⁇ g to 2 mg, preferably 10 ⁇ g to 1.8 mg, particularly preferably 10 ⁇ g to 30 ⁇ g.
• the preferred dosage form of the pharmaceutical compositions of the present invention are liquid compositions which are particularly suitable for parenteral administration, more preferably for injection, most preferably for subcutaneous injection.
• the pharmaceutical composition of the present invention is suitable for injection once a day.
• the pharmaceutical composition of the present invention may have an acidic or physiological pH.
• An acidic pH range is preferably in the range of pH 1-6.8, more preferably pH 3.5-6.8, even more preferably pH 3.5-4.5, most preferably at a pH of about 4.0 -4.5.
• a physiological pH is preferably in the range of pH 4.0 -8.5, more preferably pH 5.0 to 8.5, even more preferably pH 6.0 to 8.5.
• composition of the invention may contain a suitable preservative.
• suitable preservatives are e.g. Phenol, m-cresol, benzyl alcohol and / or p-hydroxybenzoic acid ester.
• composition according to the invention may contain a suitable buffer.
• buffer substances in particular for the adjustment of a pH value between approximately 4.0 and 8.5, eg sodium acetate, sodium citrate, sodium phosphate can be used etc. are used. Otherwise, physiologically acceptable dilute acids (typically HCl) or alkalis (typically NaOH) are also suitable for adjusting the pH.
• concentrations of the buffers and corresponding salts are in the range of 5 to 250 mM, more preferably in the range of 10 to 10 mM.
• the composition of the invention may contain zinc ions.
• the concentration of zinc ions is preferably in the range of 0 ⁇ g / ml to 500 ⁇ g / ml, more preferably from 5 ⁇ g to 200 ⁇ g zinc / ml.
• composition according to the invention may be suitable
• Contain isotonizing agent Contain isotonizing agent. Suitable examples are glycerol, dextrose, lactose, sorbitol, mannitol, glucose, NaCl, calcium or magnesium compounds such as CaCl 2, etc. Glycerol, dextrose, lactose, sorbitol, mannitol and glucose are usually in the range of 100-250 mM, NaCl in a concentration of up to 150 mM.
• composition of the invention may contain a surfactant.
• a surfactant can greatly increase the stability of acidic insulin compositions. Thus, even compositions can be prepared that guarantee the superior stability to hydrophobic aggregation germs over several months under temperature load.
• the surfactant is preferably selected from the group consisting of partial and fatty acid esters and ethers of polyhydric alcohols such as glycerol and sorbitol, polyols; wherein the partial and fatty acid ester are selected and ethers of glycerol and sorbitol from a group comprising clamping ®, Tween ®, Myrj ®, Brij ®, Cremophor ®; wherein the polyols are selected from the group consisting of polypropylene glycols, polyethylene glycols, poloxamers, polysorbates, Pluronics, Tetronics.
• Preferred concentrations of the surfactants are in the range from 5 to 200 ⁇ g / ml, preferably from 5 to 120 ⁇ g / ml and particularly preferably from 20 to 75 ⁇ g / ml.
• composition of the invention may contain other additives such as salts, which retard the release of at least one insulin.
• a particularly preferred subject of the invention is a drug as described herein comprising at least one insulin independently selected from Lys B28 Pro B29 human insulin (insulin lyspro), B28 asp human insulin (insulin aspart), B29Lys ( ⁇ -tetradecanoyl), the B30 human insulin (insulin detemir), and insulin glargine (Gly (A21) Arg (B31) Arg (B32) human insulin) and comprising AVE0010 or / and a pharmacologically tolerable salt thereof.
• Another particularly preferred article is a drug as described herein comprising insulin glargine (Gly (A21) -Arg (B31) -Arg (B32) human insulin) and AVE0010 (the Pro 36 exendin-4 (1-39) -Lys 6 - NH 2 ) or / and a pharmacologically tolerable salt thereof.
• the compositions of these particularly preferred drugs preferably have an acidic pH of 1-6.8, more preferably pH 3.5-6.8, even more preferably pH 3.5-5.0, most preferably at a pH of about 4 , 0 to 4.5. Further, the compositions of these particularly preferred drugs may contain a surfactant as described herein.
• a further subject according to the invention is a combination of insulin glargine (Gly (A21) -Arg (B31) -Arg (B32) human insulin) and AVE0010 (of Pro 36 exendin-4 (1-39) -Lys6-NH 2 ) or / and a pharmacologically tolerable salt thereof.
• Another object of the invention is methods of treating a patient with a drug or kit of the invention as described herein.
• the method according to the invention for the treatment of a patient comprises the administration of a medicament according to the invention comprising at least one insulin and at least one GLP-1 agonist, wherein the medicament is formulated or / and formulated in such a way that it contains the insulin and the GLP-1 agonist contains each predetermined amount and can be administered in each case adapted to the needs of a patient dose.
• the method comprises administering a drug comprising at least one insulin and at least one GLP-1 agonist comprising at least one insulin and / or the at least one GLP-1 agonist in different
• the method comprising:
• step (a) or / and step (b) The determination of the dose after step (a) or / and step (b) is carried out according to the individual needs of the patients.
• Step (c) of the treatment method according to the invention can be carried out on the basis of a table.
• This table may be part of the medicament of the invention.
• Example 1 1 contains an example of a table according to the invention.
• the method of treating a patient may comprise the administration of a medicament, the medicament comprising a first pharmaceutical composition and a second pharmaceutical composition and optionally at least one further pharmaceutical composition, wherein the first pharmaceutical composition comprises at least one first active agent, and wherein the second pharmaceutical composition comprises at least one first active ingredient and at least one second active ingredient, and wherein the at least one further pharmaceutical composition comprises at least one first active ingredient and at least one further active ingredient, and wherein the method comprises the steps:
• step (v) administering to the patient the amount of the second composition determined in step (ii) and optionally the amount of the at least one further composition determined in step (iii) ,
• the first drug may be an insulin and the second drug may be a GLP-1 agonist.
• the method of treating a patient may comprise, in particular, the administration of a drug, wherein the medicament comprises a first pharmaceutical composition and a second pharmaceutical composition and optionally at least one further pharmaceutical composition, wherein the first pharmaceutical composition at least one insulin, and wherein the second pharmaceutical composition comprises at least one insulin and at least one GLP-1 agonist, and wherein the at least one further pharmaceutical composition comprises at least one insulin and at least one further active ingredient, and wherein the method comprises the steps:
• the first drug may be a GLP-1 agonist
• the second drug may be insulin.
• the method of treating a patient may comprise, in particular, the administration of a drug, wherein the medicament comprises a first pharmaceutical composition and a second pharmaceutical composition Composition and optionally at least one further pharmaceutical composition, wherein the first pharmaceutical composition comprises at least one GLP-1 agonist, and wherein the second pharmaceutical composition comprises at least one GLP-1 agonist and at least one insulin, and wherein the at least one further pharmaceutical Composition comprising at least one GLP-1 agonist and at least one further active ingredient, and wherein the method comprises the steps: (i) selecting a dose of the at least one GLP-1 agonist to be administered and determining the total amount of the first, second and optionally at least one further composition such that the selected dose of the at least one GLP-1 agonist in the
• step (v) administering the amount of the second composition determined in step (ii) and optionally the amount of the at least one other
• Composition determined in step (iii) to the patient.
• Steps (i), (ii) or / and (iii) may be carried out on the basis of at least one table which may be part of the drug. For each of the Steps (i), (ii) and (iii) may be independently provided with a table.
• the treatment method according to the invention can be used in particular for the treatment of patients with diabetes, in particular with diabetes type 1 or II.
• the method is preferably used to discontinue fasting, postprandial and / or postabsorptive blood glucose concentration, to improve glucose tolerance, to prevent hypoglycemia, to prevent a functional loss of the pancreatic beta cells, to lose weight and / or to prevent weight gain.
• Another object of the invention is a process for the preparation of a medicament according to the invention comprising formulation and / or packaging, so that it contains the insulin and the GLP-1 agonist in a respectively predetermined manner
• Amount contains and can be administered in each case adapted to the needs of a patient dose.
• the medicament is preferably formulated and formulated such that one of the medicaments according to the invention described herein can be obtained, for example a medicament according to the invention comprising a first pharmaceutical composition and a second pharmaceutical composition and optionally at least one further pharmaceutical composition which in each case comprises at least one insulin and at least one GLP-1 agonist and containing at least one insulin and / or the at least one GLP-1 agonist in different proportions by weight based on the total weight of the composition.
• Fig. 1 Study design for the oral glucose tolerance test.
• Fig. 2 OGTT in the dog: effect of insulin glargine versus placebo.
• Fig. 3 OGTT in the dog: effect of AVE0010 versus placebo.
• Fig. 4 OGTT in the dog: effect of an AVEO010 / insulin glargine combination on the blood glucose level.
• Fig. 5 Dog OGTT: Effect of AVE0010 insulin glargine combination on plasma insulin and c-peptide level.
• Fig. 6 OGTT in the dog: effect of a dose reduction of AVE0010 with different ratios to insulin glargine in the combination formulation.
• Fig. 7 Effect of an AVE0010 insulin glargine combination on blood glucose in the diabetic db / db mouse.
• FIG. 9 Effect of the AVEOOIO-insulin glargine combination on the cytokine and lipotoxicity-induced ⁇ -cell apoptosis in vitro.
• Fig. 10 The "3 pens cover all" concept.
• Model oral glucose tolerance test (OGTT) in healthy dogs: comparison of the combination insulin glargine-AVE0010 with the two individual drugs.
• Insulin glargine 0.3 IU / kg sc, equivalent to 1. 8 nmol / kg. Insulin glargine is Gly (A21) Arg (B31) Arg (B32) human insulin. • AVE0010 (10 ⁇ g / kg sc in Lantus placebo formulation, equivalent to 2 nmol / kg). AVE0010 is the Pro 36 Exendin-4 (1 -39) -l_ys 6 -NH 2 .
• the data are shown in FIG.
• the combination affects the postprandial glucose increase like AVE0010 (see example 3).
• the hypoglycemic effect of insulin glargine in the postabsorptive phase is also present but attenuated (see Example 2).
• This is a synergistic effect of insulin glargine and AVE0010, as AVE0010 alone has no effect on the glucose level after glucose administration, and insulin glargine alone has no effect on the postprandial glucose level.
• Example 5
• the C-peptide is released in the conversion of proinsulin into insulin and serves as a marker of insulin secretion of the pancreatic ⁇ -cells.
• the c-peptide can be used to determine the reactivity of the pancreas.
• Figs. 5a and 5b The data are shown in Figs. 5a and 5b.
• the postprandial insulin reduction is followed by an increased postabsorptive insulin glargine level.
• C-peptide levels of the combination correspond to the insulin curve of AVE0010 during the prandial phases and insulin glargine during the postabsorptive phase.
• OGTT in dogs effect of a dose reduction of AVE0010 with different ratios to insulin glargine in the combination formulation. The experiment was carried out according to the protocol described in Example 1.
• the data are shown in FIG. A reduction of the AVE0010 dose from 10 ⁇ g / kg (see in particular Example 4) to 1 ⁇ g / kg (ie by a factor of 10) and the resulting increase in the ratio of insulin glargine to AVE0010 does not affect the synergistic activity of the combination AVE0010 with insulin glargine (see in particular Example 4). Only at significantly lower doses of AVE0010 does the effect of the combination approach the effect of insulin glargine alone (see, in particular, FIG. 2). Thus, the AVE0010 dose can be varied at least within an order of magnitude (i.e., at least a factor of 10) without losing the synergistic effect.
• Model Diabetic insulin-resistant db / db mouse: Comparison of the combination insulin glargine-AVE0010 with the two individual drugs.
• the combination AVE0010 and insulin glargine significantly better prevent apoptosis.
• the combination provides increased protection against cytokine and lipotoxicity-induced apoptosis due to this synergistic effect.
• the exemplary table in Figure 10 assumes a therapeutic range of 15 to 80 U per insulin glargine dose and 10 to 20 ⁇ g AVE0010.
• a dose of insulin glargine to be administered is predetermined.
• the predetermined dose is visited in the left column. If a corresponding AVE0010 dose in the range between 10 and 20 ⁇ g is mentioned in columns MIX A - MIX C, the corresponding MIX is selected, dosed and administered.
• the areas are overlapping: e.g. For 26 to 30 U insulin requirements Glargin Mix A or MIX B (with a higher dose of AVE0010) could be selected.
• MIX B and C If, for example, a dose of 50 U insulin is determined, then 0.5 ml of MIX B or MIX C should be dosed. This dose contains 20 ⁇ g (MIX B) or 12.5 ⁇ g (MIX C) AVEOOIO.
• This example demonstrates how a combination of two or more agents can be formulated so that when two or more compositions are combined, both agents can be administered in any amount and in any proportions. It is considered that at least one of the active ingredients should not be diluted by the combination (e.g., by mixing just before administration).
• drug A is an insulin
• drug B is a GLP-1
• Agent A may also be a GLP-1 agonist and Agent B may also be an insulin.
• a container 1 with a composition with active substance A in a concentration of a mg / ml and a container 2 with one are provided Composition with active substance B in a concentration of b mg / mL.
• a volume V 1 ml_ from container 1 and a volume V 2 ml_ from container 2 mixed.
• the volumes Vi and V 2 to be administered are chosen depending on the amount of active substances A and B to be administered.
• the volumes V 1 and V 2 of the two active ingredients are determined by the amounts of active ingredient as follows:
• Amount of active substance A V 1 ⁇ mg
• Quantity of active ingredient B V 2 ⁇ b mg
• concentrations of the active compounds A and B in the mixture of the two compositions are determined as follows.
• V 1 + V 2 is the total volume administered. This means that the two active ingredients dilute each other. Thus, it is not possible with this arrangement, for example, to maintain the concentration of the active ingredient A (eg insulin) with varying amounts of active ingredient B to a predetermined value.
• the active ingredient A eg insulin
• Container 2 provided with a composition with active ingredient A in a concentration of a mg / ml and with active ingredient B in a concentration of b mg / ml.
• the concentration of the active ingredient A is thus the same in both compositions.
• the volumes V 3 and V 2 to be administered are chosen depending on the amount of active substances A and B to be administered.
• the volumes V 3 and V 2 of the two active ingredients are determined by the amounts of active ingredient as follows: amount of active ingredient A: (V 3 ⁇ a + V 2 ⁇ a) mg amount of active ingredient B: V 2 ⁇ b mg
• V 3 + V 2 is the total volume administered. From the above calculation, it follows that the concentration of the active ingredient A is always a mg / ml, that is to say constant, no matter which volume ratio V 3 / V 2 is metered.
• volume V 2 in which the active ingredient B is given, in both cases equal.
• the total volume in the comparative example is V 1 + V 2
• This volume V 1 is smaller than the volume V 1 + V 2 of the comparative example.
• composition with active ingredient A the active ingredient B is diluted. This dilution is lower than the dilution of the active ingredient B in the comparative example (i.e., the concentration b> concentration z> concentration y):
• the dosage system according to the invention for administration of variable doses of the active ingredients A (eg an insulin) and B (eg a GLP-1 agonist) has three advantages over the comparison system:
• the concentration of the active ingredient A (eg an insulin) can to be kept constant at a predetermined value.
• the total volume to be administered is lower.
• the dilution of active substance B (eg of the GLP-1 agonist) is lower than in the comparative experiment.
• the concentration of the drug B can be more easily maintained in a predetermined range.
• the present example can be readily applied to drugs with three or more
• Active ingredients are extended, wherein the first active ingredient is contained in all compositions (preferably in equal parts by weight) and in each further composition at least one further active ingredient is contained.
• the first composition may be mixed with any further composition in any proportion without diluting the concentration of the active ingredient in the first composition.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Emergency Medicine (AREA)
• Child & Adolescent Psychology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (37)

Applications Claiming Priority (6)

Related Child Applications (3)

Publications (2)

Family

ID=42077330

Family Applications (1)

Country Status (39)

Cited By (33)

Families Citing this family (21)

Family Cites Families (401)

• 2009
  • 2009-10-09 CN CN200980150799XA patent/CN102256618A/zh active Pending
  • 2009-10-09 HU HUE19203765A patent/HUE068164T2/hu unknown
  • 2009-10-09 PT PT171691926T patent/PT3228320T/pt unknown
  • 2009-10-09 EP EP19203765.3A patent/EP3677275B1/de active Active
  • 2009-10-09 CA CA2740685A patent/CA2740685C/en active Active
  • 2009-10-09 DK DK17169192.6T patent/DK3228320T3/da active
  • 2009-10-09 BR BRPI0920881-0A patent/BRPI0920881B1/pt active IP Right Grant
  • 2009-10-09 BR BR122013025625-3A patent/BR122013025625B1/pt not_active IP Right Cessation
  • 2009-10-09 ES ES17169192T patent/ES2772731T3/es active Active
  • 2009-10-09 DK DK09783905.4T patent/DK2349324T3/en active
  • 2009-10-09 RS RS20171255A patent/RS56632B1/sr unknown
  • 2009-10-09 CR CR20170369A patent/CR20170369A/es unknown
  • 2009-10-09 EP EP09783905.4A patent/EP2349324B1/de active Active
  • 2009-10-09 CA CA3016451A patent/CA3016451A1/en not_active Abandoned
  • 2009-10-09 LT LTEP17169192.6T patent/LT3228320T/lt unknown
  • 2009-10-09 RU RU2011119639/15A patent/RU2532378C2/ru active
  • 2009-10-09 CN CN201310652176.0A patent/CN103736082A/zh active Pending
  • 2009-10-09 CN CN201510688352.5A patent/CN105396126A/zh active Pending
  • 2009-10-09 PT PT192037653T patent/PT3677275T/pt unknown
  • 2009-10-09 ES ES09783905.4T patent/ES2650621T3/es active Active
  • 2009-10-09 KR KR1020187001132A patent/KR101939557B1/ko active Active
  • 2009-10-09 LT LTEP09783905.4T patent/LT2349324T/lt unknown
  • 2009-10-09 KR KR1020167024050A patent/KR101820024B1/ko active Active
  • 2009-10-09 EP EP17169192.6A patent/EP3228320B1/de active Active
  • 2009-10-09 PE PE2011000891A patent/PE20120060A1/es active IP Right Grant
  • 2009-10-09 MX MX2016008764A patent/MX349717B/es unknown
  • 2009-10-09 MX MX2011003804A patent/MX344293B/es active IP Right Grant
  • 2009-10-09 US US13/123,835 patent/US9526764B2/en active Active
  • 2009-10-09 PL PL19203765.3T patent/PL3677275T3/pl unknown
  • 2009-10-09 HU HUE09783905A patent/HUE037449T2/hu unknown
  • 2009-10-09 PL PL17169192T patent/PL3228320T3/pl unknown
  • 2009-10-09 KR KR1020117011155A patent/KR20110084956A/ko not_active Ceased
  • 2009-10-09 PT PT97839054T patent/PT2349324T/pt unknown
  • 2009-10-09 WO PCT/EP2009/063195 patent/WO2010043566A2/de not_active Ceased
  • 2009-10-09 PL PL09783905T patent/PL2349324T3/pl unknown
  • 2009-10-09 SI SI200931768T patent/SI2349324T1/en unknown
  • 2009-10-09 HR HRP20171894TT patent/HRP20171894T1/hr unknown
  • 2009-10-09 JP JP2011531457A patent/JP5731981B2/ja active Active
  • 2009-10-09 ES ES19203765T patent/ES2992698T3/es active Active
  • 2009-10-09 RS RS20200168A patent/RS59913B1/sr unknown
  • 2009-10-09 AU AU2009305472A patent/AU2009305472B2/en active Active
  • 2009-10-09 HU HUE17169192A patent/HUE048608T2/hu unknown
  • 2009-10-09 SI SI200932040T patent/SI3228320T1/sl unknown
  • 2009-10-09 NZ NZ592283A patent/NZ592283A/xx unknown
  • 2009-10-15 AR ARP090103965A patent/AR073872A1/es not_active Application Discontinuation
  • 2009-10-15 TW TW098134861A patent/TWI494121B/zh active
  • 2009-10-16 UY UY0001032183A patent/UY32183A/es not_active Application Discontinuation
  • 2009-10-16 PA PA20098845901A patent/PA8845901A1/es unknown
• 2011
  • 2011-03-31 ZA ZA2011/02400A patent/ZA201102400B/en unknown
  • 2011-04-05 NI NI201100068A patent/NI201100068A/es unknown
  • 2011-04-06 TN TN2011000160A patent/TN2011000160A1/fr unknown
  • 2011-04-07 CR CR20110188A patent/CR20110188A/es unknown
  • 2011-04-08 MA MA33758A patent/MA32703B1/fr unknown
  • 2011-04-11 IL IL212258A patent/IL212258A/en active IP Right Grant
  • 2011-04-13 CO CO11046046A patent/CO6361944A2/es active IP Right Grant
  • 2011-04-14 DO DO2011000104A patent/DOP2011000104A/es unknown
  • 2011-04-15 CL CL2011000851A patent/CL2011000851A1/es unknown
  • 2011-04-15 HN HN2011001021A patent/HN2011001021A/es unknown
  • 2011-04-15 EC EC2011010986A patent/ECSP11010986A/es unknown
• 2012
  • 2012-10-03 JP JP2012221012A patent/JP5732016B2/ja active Active
• 2016
  • 2016-09-13 HK HK16110807.4A patent/HK1222568A1/zh unknown
  • 2016-11-01 US US15/340,969 patent/US10117909B2/en active Active
• 2017
  • 2017-09-13 IL IL254465A patent/IL254465B/en active IP Right Grant
  • 2017-12-06 CY CY20171101280T patent/CY1119952T1/el unknown
• 2018
  • 2018-10-19 US US16/165,837 patent/US20190192635A1/en not_active Abandoned
• 2020
  • 2020-02-28 HR HRP20200340TT patent/HRP20200340T1/hr unknown
• 2021
  • 2021-04-22 US US17/237,632 patent/US20220016217A1/en not_active Abandoned
• 2023
  • 2023-08-03 US US18/229,793 patent/US20240108692A1/en not_active Abandoned
• 2025
  • 2025-01-17 US US19/029,209 patent/US20250161416A1/en active Pending